Outcome of Omani Women with Breast Cancer-associated Brain Metastases Experience from a University Hospital

Zahid, Khawaja Farhan; Kumar, Shiyam; Al-Bimani, Khalid; Ahmed, Tanweer; Al-Ajmi, Adil; Burney, Ikram A.; Al-Moundhri, Mansour

doi:10.5001/omj.2019.76

Cited by 5 publications

(4 citation statements)

References 39 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Looking at original papers published from the five countries between 2011 and 2021, most analyzed datasets were of patients diagnosed before 2000 and up to the year 2012 [10,13,22,40,41,[66][67][68][69], and one meta-analysis looking at survival rates in patients with BC from the Eastern Mediterranean region included data within the same timeframe [70]. Only a couple papers reported outcome data up to year 2015 [71,72] with the absence of any outcome data from the region thereafter.…”

Section: Discussionmentioning

confidence: 99%

Breast Cancer in the Arabian Gulf Countries

Al-Shamsi,

Abdelwahed,

Abyad

et al. 2023

Cancers

View full text Add to dashboard Cite

Breast cancer stands as the prevailing malignancy across all six Gulf Cooperation Council (GCC) nations. In this literature review, we highlighted the incidence and trend of breast cancer in the GCC. Most of the studies reported a consistent increase in breast cancer incidence over the past decades, which was particularly attributed to the adoption of a Westernized lifestyle in the region and the implications of emerging risk factors and other environmental and societal factors, the increase in screening uptake, as well as the improvement in data collection and reporting in the GCC. The data on breast cancer risk factors in the GCC were limited. In this geographic region, breast cancer frequently manifests with distinctive characteristics, including an early onset, typically occurring before the age of 50; an advanced stage at presentation; and a higher pathological grade. Additionally, it often exhibits more aggressive features such as human epidermal growth factor receptor 2 (HER2) positivity or the presence of triple-negative (TN) attributes, particularly among younger patients. Despite the growing body of literature on breast cancer in the GCC, data pertaining to survival rates are, regrettably, meager. Reports on breast cancer survival rates emanating from the GCC region are largely confined to Saudi Arabia and the United Arab Emirates (UAE). In the UAE, predictive modeling reveals 2-year and 5-year survival rates of 97% and 89%, respectively, for the same period under scrutiny. These rates, when compared to Western counterparts such as Australia (89.5%) and Canada (88.2%), fall within the expected range. Conversely, Saudi Arabia reports a notably lower 5-year survival rate, standing at 72%. This disparity in survival rates underscores the need for further research directed toward elucidating risk factors and barriers that hinder early detection and screening. Additionally, there is a pressing need for expanded data reporting on survival outcomes within the GCC. In sum, a more comprehensive and nuanced understanding of breast cancer dynamics in this region is imperative to inform effective strategies for prevention, early detection, and improved patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Breast Cancer in the Arabian Gulf Countries

Al-Shamsi,

Abdelwahed,

Abyad

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Most breast cancer cases were detected at advanced stages, similar to the trend reported from the Middle Eastern countries such as Oman. 18 …”

Section: Discussionmentioning

confidence: 99%

The Relation of Haplotype ATP-binding Cassette B1 and Glutathione S-transferase P1 A313G Genes with Hematological Toxicity in Indonesian Breast Cancer Patients Receiving Chemotherapy

Syarifah¹,

Widyawati²,

Hasni³

et al. 2022

Oman Med J

View full text Add to dashboard Cite

Objectives: Hematological toxicity induced by chemotherapy is known to be caused by multiple factors, including genetic factors, such as polymorphisms. The polymorphisms may occur in drug efflux transporter proteins and enzymes involved in drug metabolism. In our study, we investigate the incidence of hematological toxicities and its relation to the haplotype ATP-Binding Cassette B1 (ABCB1) which were polymorphism of C1236T, C3435T, G2677T and Glutathione S-Transferase P1 (GSTP1) A313G gene in Indonesian breast-cancer patients who receives anthracycline during chemotherapy. Methods: One hundred and thirty-eight breast-cancer patients in H. Adam Malik Hospital, Medan, Indonesia who were in the inclusion criteria were recruited in this retrospective cohort study. The DNA of patients was extracted from the peripheral leukocytes. Single nucleotide polymorphism (SNP) ABCB1 and GSTP1 were examined by the PCR-RFLP method. Data on patient characteristics and the incidence of hematological toxicity were obtained from patient medical records after three cycles of chemotherapy. Trend of absolute neutrophil count (ANC) and anemia were analyzed using the Friedmann test and the Wilcoxon signed-rank test. The Kruskal-Wallis test was performed to understand the association of ABCB1 and GSTP1 polymorphisms with the incidence of anemia and neutropenia. The frequency distribution of genotypes and alleles were determined using the Hardy-Weinberg Equilibrium (HWE). Results: A decrease of ANC was found after post chemotherapy on cycles 3 (Mean ± SD: 5644.48± 2962.545/mm3 vs 3034.89±2049.635/mm3 ), and the anemia (12.1478±1.50057 gr/dl vs 11.2746± 1.31221 gr/dl) after the patients underwent three chemotherapy cycles (p <0.05). There was no relation between ABCB1 polymorphism, either in each SNP or in the form of haplotype (the combination of more than one SNP) on the incidence of anemia and neutropenia (p> 0.05). In GSTP1 polymorphisms, no correlation between polymorphisms and anemia and neutropenia incidence (p> 0.05) was found. In our study, the ABCB1 and GSTP1 genotypes and alleles frequency distribution showed no deviation from HWE (p> 0.05). Conclusions: Patients who have performed the three cycles of hemotherapy demonstrated a susceptibility to the side effects of hematological toxicity (such as anemia and neutropenia); however, there was no relationship between ABCB1 and GSTP1 polymorphisms to hematological toxicity.

show abstract

“…Brain metastasis is a significant factor in the decline of overall survival (OS) and degradation of the quality of life in breast cancer patients. Studies have confirmed that 20% of breast cancer patients die of brain metastases [ 2 ]. Since most drugs cannot pass through the blood–brain barrier (BBB), chemotherapy alone has a limited effect [ 3 ]; additionally, brain metastases are mostly multiple foci, which makes them difficult to be controlled by surgery [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

Yang

Ren

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Radiotherapy and targeted therapy are essential treatments for patients with brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the combination of radiotherapy and targeted therapy still needs to be investigated, and neurotoxicity induced by radiotherapy for brain metastases has also become an important issue of clinical concern. It remained unclear how to achieve the balance of efficacy and toxicity with the application of new radiotherapy techniques and new targeted therapy drugs. This article reviews the benefits and potential risk of combining radiotherapy and targeted therapy for HER2-positive breast cancer with brain metastases.

show abstract

Outcome of Omani Women with Breast Cancer-associated Brain Metastases Experience from a University Hospital

Cited by 5 publications

References 39 publications

Breast Cancer in the Arabian Gulf Countries

Breast Cancer in the Arabian Gulf Countries

The Relation of Haplotype ATP-binding Cassette B1 and Glutathione S-transferase P1 A313G Genes with Hematological Toxicity in Indonesian Breast Cancer Patients Receiving Chemotherapy

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

Contact Info

Product

Resources

About